Revere, MA, United States of America

TatFong Ng

This inventor holds 1 USPTO granted patent. Top assignee: University of Macau. Active years: 2021.


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of TatFong Ng

Introduction

TatFong Ng is an accomplished inventor based in Revere, MA (US). He has made significant contributions to the field of ocular disease treatment through his innovative research and patent work. His dedication to advancing medical science is evident in his work at the University of Macau.

Latest Patents

TatFong Ng holds a patent for "Compositions comprising a combination of a substituted flavonoid and a substituted indole for treating ocular diseases." This patent discloses compositions and methods for treating diseases or disorders of the eye and its adnexa, including dry eye disease and Sjögren's syndrome. The treatment involves administering a composition that includes an indole and a flavonoid, either as an admixture or as a synthetic heterodimer.

Career Highlights

Throughout his career, TatFong Ng has focused on developing innovative solutions for ocular health. His work has been instrumental in providing new treatment options for patients suffering from various eye conditions. His research has garnered attention in the scientific community, highlighting his expertise and commitment to improving patient outcomes.

Collaborations

TatFong Ng collaborates with Ming Yuen Lee, further enhancing the impact of his research. Their partnership exemplifies the importance of teamwork in advancing scientific knowledge and developing effective treatments.

Conclusion

TatFong Ng's contributions to ocular disease treatment through his innovative patent work demonstrate his commitment to improving healthcare. His research continues to pave the way for new therapeutic options, benefiting patients and the medical community alike.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…